CYTK — Cytokinetics, Incorporated Share News
0.000.00%
Last trade - 00:00- $8.89bn
- $8.87bn
- $88.04m
Brief: Cytokinetics Announces Launch Of Myqorzo (Aficamten) In Germany For Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
U.S. STOCKS ON THE MOVE-Catalyst Pharma, DoorDash, Tapestry
Cytokinetics dips after boosted $700 mln stock sale for heart drug
Brief: Cytokinetics Prices Public Offering Of 9.8 Mln Shares At $71/Share
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
Cytokinetics slides on stock sale plans following heart disease study
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
Brief: Cytokinetics Announces Proposed Public Offering Of Common Stock
Brief: Cytokinetics Inc - Offers Common Stock With Aggregate Public Offering Price Of $650 Million - SEC Filing
Cytokinetics Q1 revenue jumps on MYQORZO launch
Brief: Cytokinetics Q1 Basic EPS USD -1.67
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Cytokinetics jumps as heart disease drug meets goals in late-stage trial
Cytokinetics jumps as heart disease drug meets goals in late-stage trial
Cytokinetics heart disease drug meets main goals in late-stage study (updated)